

Invited Mini Review

Stem cells and reproduction

Yeonmi Lee & Eunju Kang*

Department of Convergence Medicine & Stem Cell Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea

Reproductive biotechnology has developed rapidly and is now able to overcome many birth difficulties due to infertility or the transmission of genetic diseases. Here we introduce the next generation of assisted reproductive technologies (ART), such as mitochondrial replacement technique (MRT) or genetic correction in eggs with micromanipulation. Further, we suggest that the transmission of genetic information from somatic cells to subsequent generations without gametes should be useful for people who suffer from infertility or genetic diseases. Pluripotent stem cells (PSCs) can be converted into germ cells such as sperm or oocytes in the laboratory. Notably, germ cells derived from nuclear transfer embryonic stem cells (NT-ESCs) or induced pluripotent stem cells (iPSCs) inherit the full parental genome. The most important issue in this technique is the generation of a haploid chromosome from diploid somatic cells. We hereby examine current science and limitations underpinning these important developments and provide recommendations for moving forward. [BMB Reports 2019; 52(8): 482-489]

INTRODUCTION

Around 10% of couples experience infertility (1). The etiology therein is caused by the female in 40% of cases and the male in another 40%. In 10-20% of cases, both the male and female contribute to the lack of pregnancy success, and unexplained infertility is observed in up to 10% of cases (2). Couples who suffer from fertility issues often use assisted reproductive technologies (ART), such as intrauterine insemination (IUI), *in vitro* fertilization (IVF) and intracytoplasmic sperm injection (ICSI) (3, 4). Since the first birth of an IVF baby in 1978, IVF has been the predominant treatment for female infertility (5). ICSI is an advanced ART wherein a single sperm is introduced into the oocyte through the zona pellucida via microinjection

*Corresponding author. Tel: +82-2-3010-8547; Fax: +82-2-3010-4182; E-mail: kangeun@amc.seoul.kr

<https://doi.org/10.5483/BMBRep.2019.52.8.141>

Received 15 May 2019

Keywords: Artificial oocyte, Artificial sperm, Programming, Reproduction, Stem cell

(6). The first successful ICSI was reported by Palermo *et al.* in 1992; the technique has since become a common treatment for male infertility (7).

Preimplantation genetic diagnosis (PGD) has been used in association with ART to analyze the DNA from embryos at the cleavage or blastocyst stage to determine genetic abnormalities (8). Recent techniques isolate a few cells from the trophectoderm that will become placenta or amnion during embryo development. These isolated cells can be genetically sequenced for disease mutations, and embryos negative for these mutations can then be transplanted into the mother. Multiple rounds of IVF are frequently needed to obtain healthy embryos. ART increases the chance of delivering a healthy baby without heritable genetic disorders caused by known mutations or chromosomal abnormalities (9).

However, it is significantly more difficult to predict the transmission of mitochondrial DNA (mtDNA) mutations by PGD due to asymmetric segregation of mtDNA (10, 11). Homozygous nuclear mutations, even rarely-occurring ones, cannot be screened out by PGD because all oocyte or sperm will contain the given mutation, leaving no embryos available for pregnancy. Alternatives are thereby urgently needed to avoid the potential transmission of mtDNA-based disorders or homozygous nuclear mutations.

CURRENT APPLICABLE ASSISTED REPRODUCTIVE TECHNOLOGIES

Mitochondrial replacement therapy (MRT) is a series of processes that involve extracting nuclear DNA with a small amount of cytoplasm from an oocyte or zygote in a patient with mutated mtDNA and then transplanting it into donor cytoplasm where the donor's nucleus has been removed, replacing it with non-mutated mtDNA from the donor (12). Currently, there is no cure for mitochondrial disease, and MRT is the only technology proposed to eliminate the risk of disease inheritance in offspring. Advanced female age is another important cause of infertility, partially due to a cytoplasmic deficiency which induces chromosomal abnormalities in aged oocytes resulting in the failure of fetal development. MRT can also be employed to resolve cytoplasmic defects due to aging (13).

There are several methods for MRT, including pronuclear transfer (PNT), spindle transfer (ST), and polar body transfer

(PBT) (Fig. 1). Initially, PN transfer from one zygote to another was performed, and a reconstructed mouse zygote was shown to develop into a live offspring (14). However, a high carryover of mutated mtDNA was detected in the tissues of PNT offspring due to the large amount of cytoplasm that must be physically maintained around the substituted PN structure. Lower levels of mtDNA carryover were shown, however, by performing PNT in human embryo development (15).

ST was pioneered in the monkey and has demonstrated the efficiency and safety of MRT verified by normal growth in the live birth and low levels of mtDNA carryover (16). Based on an ST study in the monkey, human ST was performed using oocytes with different mtDNA haplotypes for mtDNA tracking (17). In ST embryos, embryonic development and ESC establishment rates were similar to control IVF. In ESCs derived from ST embryos, mtDNA carryover levels were undetectable, however, certain haplotype combinations were reverted to maternal mtDNA, meaning 100% carryover (18). The world's first ST baby was born in Mexico (19). The mother harbored the mtDNA 8993T>G mutation for Leigh syndrome, and ST was carried out in order to avoid the transmission of this disease to her child.

PBT is performed with residual nuclei (PB1 or PB2) not used




Fig. 1. Current applicable assisted reproductive technologies for mitochondrial replacement. From an MII oocyte with mutated mtDNA, spindle or PB1 is isolated and transferred to an enucleated MII oocyte with healthy mtDNA. Reconstructed oocytes by ST or PB1T are fertilized with sperm. In the zygote with mutated mtDNA, PNs or PB2 can be transferred for PNT while only one PN is for PB2T. For SCNT, the fibroblasts carrying mutant mtDNA are transferred to enucleated MII oocytes with healthy mtDNA. Reconstructed SCNT oocytes are activated artificially. Embryos with healthy mtDNA can develop into ESCs or offspring. MII, metaphase II; mtDNA, mitochondrial DNA; ST, spindle transfer; PB1T, 1st polar body transfer; PB2T, 2nd polar body transfer; PNT, pronucleus transfer; SCNT, somatic cell nuclear transfer; ESCs, embryonic stem cells.

in PNT or ST and can increase the yield of treated embryos after MRT. During meiosis, mammalian oocytes undergo two reductive cleavages through uneven cytoplasmic separation and two small body abstractions (polar body), harboring chromosomes. The first polar body (PB1) contains diploid chromosomes, and the second polar body (PB2) contains a haploid chromosome. In the mouse, PBT demonstrated normal meiosis in reconstructed oocytes and production of viable offspring (20, 21). In humans, reconstructed PBT oocytes completed for meiosis after fertilization with sperm, while in general, PBT-derived blastocysts gave rise to phenotypically normal ESC lines (22).

However, MRT does involve certain issues. First, a significant increase in the number of healthy egg donors and patient eggs would be required to conduct the necessary research, not to mention its clinical application. Second, poor sperm quality or azoospermia in the partner could limit the application of MRT through ICSI. MRT is also not appropriate for the treatment of nuclear genetic diseases with homozygous mutations, as such mutations will be present in all embryos generated by the MRT.

ASSISTED REPRODUCTIVE TECHNOLOGIES FOR THE FUTURE

Oocytes or sperm can be differentiated from pluripotent stem cells

If oocytes and sperm could be made from adult somatic cells,




Fig. 2. The entire cycle of germ cell differentiation and reprogramming for reproduction. PGCs are naturally produced from epiblast cells, which are generated from ICM. The PGCs migrate to the fetus and take up residence in the ovaries or testes, where they develop into oocytes or sperm, respectively. *In vitro* experiments, iPSCs, and ESCs could be differentiated to germ cells, which could then develop into blastocysts. Blastocysts could be developed to ESCs *in vitro* or body *in vivo*. The body naturally harbors germ cells, and somatic cells in the body could be reprogrammed to derive iPSCs. PSCs, pluripotent stem cells; PGCs, primordial germ cells; ICM, inner cell mass; iPSCs, induced pluripotent stem cells; ESCs, embryonic stem cells.

they could be used for people who suffer from infertility or genetic diseases (23) (Fig. 2). Oocytes or sperm have not yet been effectively produced using human pluripotent stem cells (PSCs). In 2011, Katsuhiko Hayashi and his colleagues showed that sperm and oocytes generated from male or female PSCs enabled an infertile mouse to have healthy pups for the first time (24, 25). Primordial germ cells (PGCs) are naturally generated from epiblast cells, which are developed from ICM after embryo implantation. PGCs migrate back to the fetus and reside in the ovaries or testes, where they develop into eggs or sperm, respectively. In *in vitro* oogenesis, PSCs were induced to develop into epiblast-like cells, which were then induced to become PGC-like cells (26); these PGC-like cells differentiated to primary oocytes. These primary oocytes developed into GV oocytes, which were matured to functional MII oocytes. One limitation therein is that gonad somatic cells are required for the generation of the primary oocyte from PGC-like cells.

This limitation also appeared *in vitro* spermatogenesis where testicular tissue was used for differentiation of sperm from PSCs (27). In humans, spermatids were generated from human spermatogonial stem cells (SSCs) *in vitro* (28). However, complete *in vitro* spermatogenesis starting from human PSCs has yet to be achieved. In *in vitro* oogenesis, oogonia have been induced from human PSCs (29). Ovarian follicle-like cells have also been generated from PSCs overexpressing *DAZL* and *BOULE* *in vitro* (30).

Although a great deal of mouse research has been performed for oogenesis and spermatogenesis, it is inappropriate to attempt to apply such research directly to humans. Three main factors must be considered before human application. First, the initiating cell type for oogenesis or spermatogenesis is critical. Some researchers reported generation of epiblast stem cells (31-33), but Hayashi and colleagues claimed that these cells did not produce PGCs. Instead, they generated epiblast-like cells from mouse embryonic stem cells (ESCs), which developed into PGCs, and later oocytes or sperm (34). Second, converting PSCs to specific types of cells is challenging, and not all cells respond equally. If PSCs do not differentiate into PGCs, certain cells may differentiate into unwanted cell type instead; as such, purification of PGCs is important to eliminate potential unwanted cell types. Third, to generate functional sperm or oocytes from PSCs, they still must be transplanted into the ovaries or testes, or gonad cells if they are generated *in vitro* without transplantation (24, 26). Identifying and replicating how PGCs mature in the ovaries or testes *in vitro* is crucial for minimizing the number of invasive procedures required for PGCs maturation.

Cure of genetic diseases in germ cells

In the case of a couple carrying a genetic mutation, PGD, which is the clinical standard for treating genetic diseases, is currently the only way to avoid transplantation of mutated embryos. Recently, DNA cutting techniques known as CRISPR/Cas9 (35), have been modified to edit genes in

embryos directly. Researchers attempting to edit human embryos using CRISPR have made some progress (36). Several scientific groups in China have reported genetic correction with CRISPR/Cas9 in human zygotes (37, 38). Recently, Ma *et al.* (35) described the correction of a pathogenic mutation in human embryos with CRISPR technology; they corrected the heterozygous *MYBPC3* mutation with high HDR efficiency. Other studies were the first to use a base editor system to correct the *HBB* (A>G) mutation in a human embryonic genome (39, 40). This suggests great potential for modifying homozygous and complex heterozygous mutations by base editing in human embryos. In 2018, a Chinese scientist, He Jiankui, claimed to have produced the world's first genome-edited babies, twin girls, one of which was purported to have HIV resistance due to the disabling of both copies of the *CCR5* gene by CRISPR/Cas9 technique. However, this technique can also affect non-target DNA, requires multiple embryos, and is thus beset with many ethical obstacles.

If PSCs could produce oocytes or sperm, they could be useful for gene correction. There are several ways to treat genetic diseases in PSCs. Using CRISPR/Cas9 technology, DNA can be added or removed to modify mutations, after which only corrected cells would be selected for proliferation. This means that all oocytes and sperm generated by modified PSCs would not have the disease. Unintended mutations that might occur during this process could be removed before the conversion to oocytes or sperm. Second, in the case of mosaic disease (a disease that does not affect all cells) including extra chromosomes, PSCs without this syndrome could be isolated and converted into oocytes and sperm. However, such corrective techniques are not used to prevent genetic disease because currently, standard clinical PGD is cheaper and more efficient.

PLURIPOTENT STEM CELLS (PSCS) AS A SOURCE OF GERM CELLS

In the future, we anticipate being able to generate sperm or oocytes from PSCs for oocyte- or sperm-free patients (Fig. 2). Thus far, the main source of artificial germ cells is PSCs. Below, we introduce cell types, advantages, and disadvantages of PSCs (Fig. 3).

PSCs and reproduction are closely related. The first PSC was isolated from the inner cell mass (ICM) of a blastocyst in 1981, calling to embryonic stem cells (ESCs) (41). PSCs can differentiate into any type of cell in the body, not only the muscles, nerves, and skin cells, but oocytes and sperm as well, although not the placenta. Human ESCs were first established in 1998 and are used in many stem cell fields (42). During *in vitro* culture, PSCs rapidly proliferate and regenerate to produce enough cells for disease treatment, drug screening, and disease modeling (43).

Mouse ESCs express pluripotent markers such as Oct4, Sox2, Nanog, and Ssea1, and could contribute to both somatic




Fig. 3. Current available PSCs types. Regular ESCs, produced from IVF embryos, represent an ideal stem cell source for regenerative medicine; however, ethical and technical limitations regarding human use thereof remain barriers to their research and use. Uniparental ESCs include an entire maternal parthenogenetic ESCs) or paternal (androgenetic ESCs) genome. To produce a parthenogenetic embryo, MII oocytes are activated artificially. Heterozygous or homozygous parthenogenetic ESCs can be generated depending on extrusion of the second polar body; extrusion for homozygous or no extrusion for heterozygous ESCs. Another method involves removing the male pronucleus from the zygote. In the generation of androgenetic embryos, the female pronucleus is removed from the zygote. Another approach is the removal of the nucleus from MII oocytes and replaces it with sperm head. These uniparental ESCs are usually generated for research, with no possibility for clinical applications currently. Fibroblasts could be reprogrammed to PSCs by SCNT or iPSC generation. The SCNT technique can cure mitochondrial disease because mtDNA mutated fibroblasts are transferred to enucleated MII oocytes with healthy mtDNA; the derived SCNT-ESCs then harbor healthy mtDNA. However, this is prevented by ethical issues surrounding oocyte use. While iPSCs are unfettered by ethical concerns, these are produced from mtDNA mutated fibroblasts directly and will still include mutated mtDNA after reprogramming. PSCs, pluripotent stem cells; ESCs, embryonic stem cells; IVF, *in vitro* fertilization; MII, metaphase II; SCNT, somatic cell nuclear transfer; iPSCs, induced pluripotent stem cells; mtDNA, mitochondrial DNA.

and germ cells in the chimeric mouse. The first primate ESC was successfully isolated from the rhesus monkey in 1995 (44). Three years later, the same team reported ESCs isolated from human embryos produced by IVF for reproductive purposes. Although human ESCs represent the greatest potential for creating IVF embryos, they are allogeneic with regards to potential recipients, and their derivation and use have ethical and technical limitations (45). There are, however, alternative PSC types that could be used for regenerative medicine: induced pluripotent stem cells (iPSCs),

homozygous ESCs derived by parthenogenesis or androgenesis, and ESCs derived by somatic cell nuclear transfer (NT-SCNT).

Induced pluripotent stem cells (iPSCs)

In 2006, Japanese scientist Shinya Yamanaka showed that mouse skin cells could be made into pluripotent stem cells through reprogramming (46). Although these cells originated from somatic cells, they were called induced pluripotent stem cells (iPSCs) due to their similarities to ESCs. Yamanaka's team succeeded in transforming adult fibroblasts into iPSCs using four transcription factors: Oct4, Sox2, c-Myc, and Klf4 (46-48). These iPSCs were similar in morphology to ESCs and are capable of forming teratomas including all three germ layers. In mice, fertile adult mice were successfully generated from iPSCs (germline transmission) with tetraploid complementation.

iPSC has become an attractive alternative for autologous or allogeneic transplantation by overcoming the ethical concerns and immunogenicity of human ESCs. However, iPSCs have been reported to have several important limitations related to incomplete erasure of epigenetic markings and genetic instability. There is some evidence that they retain residual epigenetic memory, typical of parental somatic cells (49), which may lead to bias in their propensity to differentiate to different lineages (50).

Somatic cell nuclear transfer embryonic stem cells (NT-ESCs)

The somatic cell nuclear transfer (SCNT) procedure includes three major steps: enucleation, donor cell injection and fusion, and activation (51). After removing the oocyte nucleus, the donor cell nucleus is injected and fused with enucleated oocytes. Reconstructed oocytes are artificially activated to initiate a developmental program and form blastocysts. Since its initial discovery in amphibians (52), SCNT success has produced cloned offspring across a range of mammalian species including horse, cow, sheep, goat, dog, cat, wolf, pig, rabbit, ferret, and monkey, suggesting that the reprogramming activity of enucleated oocytes is universal (51). The efficiency of cloning varied, however, depending on tissue origin, stem cell potency, and strain of nuclear donor cells (53-55).

Using SCNT protocols optimized in monkeys, human SCNT and NT-ESC derivations have been successful (56). Three main factors are necessary for the successful human SCNT. First, somatic cell nuclei must form spindle-like structures when caffeine is incorporated to prevent premature activation. Second, somatic cell fusion must be performed with HVJ-E, which protects the cytoplasm from premature activation. Third, the combination of electroporation and TSA improves SCNT reprogramming and blastocyst development. Serially, human SCNT was attempted using fibroblasts originated from elderly and type 1 diabetes patients (50, 57). Initial gene expression and transcripts of pluripotency-related genes were similar between NT-ESCs and IVF-ESCs (49). In addition, NT-ESCs clustered more closely with the IVF-ESCs than iPSCs

(58). Based on the SCNT technique optimizations and outcomes; however, while the protocol for NT-ESC derivation has been proven, its feasibility is inhibited by the relatively limited availability and high cost of human oocytes. Clinical applications of human NT-ESCs for allogeneic use, however, are possible (45).

Uniparental ESCs

Uniparental embryos contain the entire paternal (androgenetic embryo) or maternal (parthenogenetic embryo) inherited genome. Uniparental embryos have been generated from a variety of mammalian species including primates and humans (59). Mammalian uniparental embryos can produce ESCs but cannot produce offspring (59).

Parthenogenesis is a maternally uniparental reproduction (43). Activated oocytes with inhibited second polar body extrusion form pseudodiploid parthenogenetic embryos. Sister chromatids are separated but remain in the oocyte cytoplasm. These oocytes enter mitosis resulting in the development of diploid, partially heterozygous embryos due to crossover, and develop into blastocysts at a rate similar to fertilized embryos (60). Similar to natural activation, when the activated oocyte extracts the second polar body and induces the completion of meiosis, the parthenogenetic embryo includes a haploid genome. Embryos have thus been developed with abnormal placentation and other abnormal fetal development (61). However, parthenogenetic ESCs in mice can generate live pups through tetraploid embryo complementation, wherein recipient embryos contribute placenta only (62). These parthenogenetic ESCs are similar to IVF-ESCs in terms of morphology, growth, global transcription profile, and genes involved in pluripotency (63).

Androgenetic ESCs have been established from embryos obtained by replacing the oocyte nucleus with sperm or by removing the female pronucleus from the zygote (64, 65). Androgenetic ESCs showed haploid-originated homozygosity because they were derived from embryos reconstructed with a single sperm or male pronucleus (66). These ESCs also showed similar characteristics to IVF-ESCs.

Haploid ESCs

Haploid ESCs have been derived from two types of haploid embryos: a parthenogenetic embryo with oocyte nucleus, and an androgenetic embryo with the sperm nucleus. To produce a parthenogenetic haploid embryo, a second polar body must be excluded, similar to what occurs in natural activation (67). Another method involves removing the male pronucleus from the fertilized zygote. In contrast, removal of the female pronucleus from the zygote generates an androgenetic embryo containing only a haploid paternal genome. Another approach to generating androgenetic haploid embryos is to remove the nucleus of the mature oocyte and replace it with sperm head. Since the 1970s, attempts to create haploid embryos in mice have been undertaken to understand different gene functions

at early developmental stages (68). In 2011, haploid ESCs from parthenogenetic haploid embryos were generated (69), leading to the establishment of androgenetic haploid ESCs (64, 65).

Androgenetic and parthenogenetic haploid ESCs show differences in gene expression due to paternal versus maternal imprints. However, both types of haploid ESCs share many characteristics with normal diploid ESCs, including gene expression pattern, *in vitro* differentiation potential, and chimeric ability after blastocyst injection (70). Injecting haploid ESC into blastocysts contributes significantly to the development of chimeric mice. During development, however, most haploid cells become diploid (70). These results indicate that uniparental diploid cells could contribute to the development of chimeric mice. Diploidization is a common observation in the differentiation of haploid ESC cultures (70). Its mechanism is largely unknown, but a point during the cleavage process wherein the haploid genome is replicated without cell division has been occurred (43).

A haploid cell is a valuable tool for genetic screening. Heterozygous mutations in diploid cells often show few or no phenotypic changes, rendering them unsuitable for studying recessive mutations (70). Mutations introduced into a haploid genome are in a hemizygous state and are phenotypically exposed; large pools of haploid cells with different mutations are thereby useful for screening (70). Haploid cells have shown homozygosity at HLA loci, a potential source of cell therapy that could avoid immune rejection in allotransplantation (66). Haploid cells could thereby be matched to other patients with less risk of immunological rejection.

LIMITATIONS

Oocytes derived from male cells or sperm from female cells

There are several studies suggesting XY (male) primordial germ cells could naturally produce XX oocytes *in vivo* (71) and oocyte-like cell production from male multipotent cells (72, 73). However, decades of studies on mammalian gamete formation and sex determination have determined that it is not possible to form oocytes from cells with a Y chromosome nor sperm from cells without Y chromosome (74). Furthermore, most of the current studies focused on genetic dysfunction in oocytes and sperm (ovaries and testes), no studies have demonstrated successful production of oocytes from XY (male) cells or sperm from XX (female) cells.

Embryo creation using sperm and oocytes from the same individual

Although it is possible to produce embryos from oocytes or sperm from a single individual, the possibility of genetically identical embryos is extremely rare. There are 23 chromosomes in oocytes and sperm made from pluripotent stem cells (PSC) that represent a random mix of chromosomes from the individual's mother and father. The fusion of a random oocyte chromosome and a random sperm chromosome produce an

enormous variety of different children; the sheer number of potential combinations thereof precludes the production of genetically identical babies. Mixing chromosomes for the production of oocytes and sperm are a survival advantage, and a prohibitively large number of children would be needed for the production of a child genetically identical to one of its siblings by the same parents. Cloning takes genetic information from a single somatic donor cell (46 chromosomes) and transplants it into an oocyte wherein the genetic material (nucleus) has been removed. These embryos are thus completely identical to one another (clones) in all cases. However, the use of cloning in human reproduction is prohibited worldwide.

Somatic cell haploidization

It has been suggested that the haploidization of the diploid somatic cell can be induced using enucleated oocytes (75). If diploid cell nuclei are transferred into immature or maturing oocytes, the cytoplasm might induce the separation of the diploid chromosome. This possibility has been studied using enucleated immature oocytes and cumulus cells as donor cells in the mouse; however, researchers concluded that the mitotic cell nucleus could not be induced to normal haploidization with chemical activation (76). Allocation of the chromatin on the meiotic spindle was abnormal, and separation of the mitotic chromosomes was similarly aberrant. In humans, somatic cell haploidization has also been tried with mature oocyte and cumulus cells, resulting in two PN zygotes produced by ICSI introducing the male parent's sperm into the reconstructed oocyte (77). However, further research in embryonic development and the possibility of establishing ESCs has yet to be conducted. At present, the potential for somatic cell haploidization remains unclear.

There are limitations to the use of somatic cells for ART. First, epigenetic memory must be contended with. Epigenetic memory is important for modulating gene functions such as genetic imprinting (78). During reprogramming, the epigenome of mature somatic cells undergoes massive rearrangements (79). A somatic cell nucleus must cease its original gene expression and re-establish the embryonic gene expression necessary for normal development. (80). However, such epigenetic rearrangements have not yet been sufficient to erase all epigenetic memory during reprogramming. In addition, egg donors are required to use somatic cell haploidization for research and clinical applications. Finally, in pre-clinical studies, a large number of oocytes are required to study the mechanism of somatic cell haploidization, but the number of eggs available with which to do so is limited. To overcome this limitation, the generation of artificial oocytes from somatic cells such as PSCs could be an alternative for research and clinical applications that would circumvent current ethical concerns.

ACKNOWLEDGEMENTS

The study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1A2B3001244 and 2018R1D1A1B07043216).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Sherrod RA (2004) Understanding the emotional aspects of infertility: Implications for nursing practice. *J Psychosoc Nurs Ment Health Serv* 42, 40-47
2. Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF and Jamieson DJ (2015) Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. *JAMA* 313, 255-263
3. Verhaak CM, Smeenk JM, Evers AW, Kremer JA, Kraaijmaat FW and Braat DD (2007) Women's emotional adjustment to IVF: A systematic review of 25 years of research. *Hum Reprod Update* 13, 27-36
4. Maleki-Saghooni N, Amirian M, Sadeghi R and Latifnejad Roudsari R (2017) Effectiveness of infertility counseling on pregnancy rate in infertile patients undergoing assisted reproductive technologies: A systematic review and meta-analysis. *Int J Reprod Biomed (Yazd)* 15, 391-402
5. Edwards RG, Steptoe PC and Purdy JM (1980) Establishing full-term human pregnancies using cleaving embryos grown in vitro. *Br J Obstet Gynaecol* 87, 737-756
6. Devroey P and Van Steirteghem A (2004) A review of ten years experience of ICSI. *Hum Reprod Update* 10, 19-28
7. Palermo G, Joris H, Devroey P and Van Steirteghem AC (1992) Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet* 340, 17-18
8. Zegers-Hochschild F, Adamson GD, Dyer S et al (2017) The international glossary on infertility and fertility care. *Fertil Steril* 108, 393-406
9. Vaiarelli A, Cimadomo D, Capalbo A et al (2016) Pre-implantation genetic testing in ART: Who will benefit and what is the evidence? *J Assist Reprod Genet* 33, 1273-1278
10. Lee HS, Ma H, Juanes RC et al (2012) Rapid mitochondrial DNA segregation in primate preimplantation embryos precedes somatic and germline bottleneck. *Cell Rep* 1, 506-515
11. Steffann J, Frydman N, Gigarel N et al (2006) Analysis of mtDNA variant segregation during early human embryonic development: A tool for successful NARP preimplantation diagnosis. *J Med Genet* 43, 244-247
12. Wolf DP, Mitalipov N and Mitalipov S (2015) Mitochondrial replacement therapy in reproductive medicine. *Trends Mol Med* 21, 68-76
13. Tachibana M, Kuno T and Yaegashi N (2018) Mitochondrial replacement therapy and assisted reproductive technology: A paradigm shift toward treatment of genetic

- diseases in gametes or in early embryos. *Reprod Med Biol* 17, 421-433
14. McGrath J and Solter D (1983) Nuclear transplantation in the mouse embryo by microsurgery and cell fusion. *Science* 220, 1300-1302
 15. Hyslop LA, Blakeley P, Craven L et al (2016) Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. *Nature* 534, 383-386
 16. Tachibana M, Sparman M, Sritanaudomchai H et al (2009) Mitochondrial gene replacement in primate offspring and embryonic stem cells. *Nature* 461, 367-372
 17. Tachibana M, Amato P, Sparman M et al (2013) Towards germline gene therapy of inherited mitochondrial diseases. *Nature* 493, 627-631
 18. Kang E, Wu J, Gutierrez NM et al (2016) Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. *Nature* 540, 270-275
 19. Zhang J, Liu H, Luo S et al (2017) Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. *Reprod Biomed Online* 34, 361-368
 20. Wakayama T and Yanagimachi R (1998) The first polar body can be used for the production of normal offspring in mice. *Biol Reprod* 59, 100-104
 21. Wakayama T, Hayashi Y and Ogura A (1997) Participation of the female pronucleus derived from the second polar body in full embryonic development of mice. *J Reprod Fertil* 110, 263-266
 22. Ma H, O'Neil RC, Marti Gutierrez N et al (2017) Functional human oocytes generated by transfer of polar body genomes. *Cell Stem Cell* 20, 112-119
 23. Reproduction and fertility: How could stem cells help? <https://www.eurostemcell.org/reproduction-and-fertility-how-could-stem-cells-help>
 24. Hayashi K, Ohta H, Kurimoto K, Aramaki S and Saitou M (2011) Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Cell* 146, 519-532
 25. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H and Saitou M (2012) Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. *Science* 338, 971-975
 26. Hikabe O, Hamazaki N, Nagamatsu G et al (2016) Reconstitution in vitro of the entire cycle of the mouse female germ line. *Nature* 539, 299-303
 27. Zhou Q, Wang M, Yuan Y et al (2016) Complete meiosis from embryonic stem cell-derived germ cells in vitro. *Cell Stem Cell* 18, 330-340
 28. Sun M, Yuan Q, Niu M et al (2018) Efficient generation of functional haploid spermatids from human germline stem cells by three-dimensional-induced system. *Cell Death Differ* 25, 747-764
 29. Yamashiro C, Sasaki K, Yabuta Y et al (2018) Generation of human oogonia from induced pluripotent stem cells in vitro. *Science* 362, 356-360
 30. Jung D, Xiong J, Ye M et al (2017) In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells. *Nat Commun* 8, 15680
 31. Rathjen J, Lake JA, Bettess MD, Washington JM, Chapman G and Rathjen PD (1999) Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. *J Cell Sci* 112 (Pt 5), 601-612
 32. Tesar PJ, Chenoweth JG, Brook FA et al (2007) New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* 448, 196-199
 33. Brons IG, Smithers LE, Trotter MW et al (2007) Derivation of pluripotent epiblast stem cells from mammalian embryos. *Nature* 448, 191-195
 34. Hayashi M, Kawaguchi T, Durcova-Hills G and Imai H (2017) Generation of germ cells from pluripotent stem cells in mammals. *Reprod Med Biol* 17, 107-114
 35. Ma H, Marti-Gutierrez N, Park SW et al (2017) Correction of a pathogenic gene mutation in human embryos. *Nature* 548, 413-419
 36. Zhang C, Quan R and Wang J (2018) Development and application of CRISPR/Cas9 technologies in genomic editing. *Hum Mol Genet* 27, R79-R88
 37. Tang L, Zeng Y, Du H et al (2017) CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. *Mol Genet Genomics* 292, 525-533
 38. Kang X, He W and Huang Y (2016) Introducing precise genetic modifications into human 3PN embryos by CRISPR/cas-mediated genome editing. *J Assist Reprod Genet* 33, 581-588
 39. Liang P, Ding C, Sun H et al (2017) Correction of beta-thalassemia mutant by base editor in human embryos. *Protein Cell* 8, 811-822
 40. Zhou C, Zhang M, Wei Y et al (2017) Highly efficient base editing in human tripronuclear zygotes. *Protein Cell* 8, 772-775
 41. Evans MJ and Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292, 154-156
 42. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145-1147
 43. Daughtry B and Mitalipov S (2014) Concise review: Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features. *Stem Cells Transl Med* 3, 290-298
 44. Thomson JA, Kalishman J, Golos TG et al (1995) Isolation of a primate embryonic stem cell line. *Proc Natl Acad Sci U S A* 92, 7844-7848
 45. Wolf DP, Morey R, Kang E et al (2017) Concise review: Embryonic stem cells derived by somatic cell nuclear transfer: A horse in the race? *Stem Cells* 35, 26-34
 46. Takahashi K and Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663-676
 47. Okita K, Ichisaka T and Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. *Nature* 448, 313-317
 48. Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861-872
 49. Ma H, Morey R, O'Neil RC et al (2014) Abnormalities in human pluripotent cells due to reprogramming mechanisms. *Nature* 511, 177-183
 50. Yamada M, Johannesson B, Sagi I et al (2014) Human oocytes reprogram adult somatic nuclei of a type 1

- diabetic to diploid pluripotent stem cells. *Nature* 510, 533-536
51. Matoba S and Zhang Y (2018) Somatic cell nuclear transfer reprogramming: Mechanisms and applications. *Cell Stem Cell* 23, 471-485
 52. GURDON JB (1962) The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. *J Embryol Exp Morphol* 10, 622-640
 53. Thuan NV, Kishigami S and Wakayama T (2010) How to improve the success rate of mouse cloning technology. *J Reprod Dev* 56, 20-30
 54. Inoue K, Ogonuki N, Mochida K et al (2003) Effects of donor cell type and genotype on the efficiency of mouse somatic cell cloning. *Biol Reprod* 69, 1394-1400
 55. Wakayama S, Ohta H, Kishigami S et al (2005) Establishment of male and female nuclear transfer embryonic stem cell lines from different mouse strains and tissues. *Biol Reprod* 72, 932-936
 56. Tachibana M, Amato P, Sparman M et al (2013) Human embryonic stem cells derived by somatic cell nuclear transfer. *Cell* 153, 1228-1238
 57. Chung YG, Eum JH, Lee JE et al (2014) Human somatic cell nuclear transfer using adult cells. *Cell Stem Cell* 14, 777-780
 58. Ziller MJ, Muller F, Liao J et al (2011) Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. *PLoS Genet* 7, e1002389
 59. Dinger TC, Eckardt S, Choi SW et al (2008) Androgenetic embryonic stem cells form neural progenitor cells in vivo and in vitro. *Stem Cells* 26, 1474-1483
 60. Mitalipov SM, Nusser KD and Wolf DP (2001) Parthenogenetic activation of rhesus monkey oocytes and reconstructed embryos. *Biol Reprod* 65, 253-259
 61. Tarkowski AK, Witkowska A and Nowicka J (1970) Experimental parthenogenesis in the mouse. *Nature* 226, 162-165
 62. Chen Z, Liu Z, Huang J et al (2009) Birth of parthenote mice directly from parthenogenetic embryonic stem cells. *Stem Cells* 27, 2136-2145
 63. Sritanaudomchai H, Ma H, Clepper L et al (2010) Discovery of a novel imprinted gene by transcriptional analysis of parthenogenetic embryonic stem cells. *Hum Reprod* 25, 1927-1941
 64. Yang H, Shi L, Wang BA et al (2012) Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. *Cell* 149, 605-617
 65. Li W, Shuai L, Wan H et al (2012) Androgenetic haploid embryonic stem cells produce live transgenic mice. *Nature* 490, 407-411
 66. Ding C, Huang S, Qi Q et al (2015) Derivation of a homozygous human androgenetic embryonic stem cell line. *Stem Cells Dev* 24, 2307-2316
 67. Paffoni A, Brevini TA, Gandolfi F and Ragni G (2008) Parthenogenetic activation: Biology and applications in the ART laboratory. *Placenta* 29 Suppl B, 121-125
 68. Graham CF (1974) The production of parthenogenetic mammalian embryos and their use in biological research. *Biol Rev Camb Philos Soc* 49, 399-424
 69. Leeb M and Wutz A (2011) Derivation of haploid embryonic stem cells from mouse embryos. *Nature* 479, 131-134
 70. Wutz A (2014) Haploid mouse embryonic stem cells: Rapid genetic screening and germline transmission. *Annu Rev Cell Dev Biol* 30, 705-722
 71. Ford CE, Evans EP, Burtenshaw MD, Clegg HM, Tuffrey M and Barnes RD (1975) A functional 'sex-reversed' oocyte in the mouse. *Proc R Soc Lond B Biol Sci* 190, 187-197
 72. Hubner K, Fuhrmann G, Christenson LK et al (2003) Derivation of oocytes from mouse embryonic stem cells. *Science* 300, 1251-1256
 73. Qing T, Shi Y, Qin H et al (2007) Induction of oocyte-like cells from mouse embryonic stem cells by co-culture with ovarian granulosa cells. *Differentiation* 75, 902-911
 74. Takeeto T (2015) The role of sex chromosomes in mammalian germ cell differentiation: Can the germ cells carrying X and Y chromosomes differentiate into fertile oocytes? *Asian J Androl* 17, 360-366
 75. Tsai MC, Takeuchi T, Bedford JM, Reis MM, Rosenwaks Z and Palermo GD (2000) Alternative sources of gametes: Reality or science fiction? *Hum Reprod* 15, 988-998
 76. Fulka J Jr, Martinez F, Tepla O, Mrazek M and Tesarik J (2002) Somatic and embryonic cell nucleus transfer into intact and enucleated immature mouse oocytes. *Hum Reprod* 17, 2160-2164
 77. Tesarik J, Nagy ZP, Sousa M, Mendoza C and Abdelmassih R (2001) Fertilizable oocytes reconstructed from patient's somatic cell nuclei and donor ooplasts. *Reprod Biomed Online* 2, 160-164
 78. Halley-Stott RP and Gurdon JB (2013) Epigenetic memory in the context of nuclear reprogramming and cancer. *Brief Funct Genomics* 12, 164-173
 79. Maherali N, Sridharan R, Xie W et al (2007) Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. *Cell Stem Cell* 1, 55-70
 80. Marcin Samiec MS (2018) Can reprogramming of overall epigenetic memory and specific parental genomic imprinting memory within donor cell-inherited nuclear genome be a major hindrance for the somatic cell cloning of mammals? - A review. *Annals of Animal Science (Ann Anim Sci)* 18, 623-638